{
    "nct_id": "NCT03935685",
    "official_title": "Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy",
    "inclusion_criteria": "* Understand and voluntarily sign and date an informed consent document prior to any study related assessments/procedures are conducted.\n* Histologically confirmed diagnosis of glioma\n* No prior treatment with temozolomide TMZ\n* Patient will receive temozolomide TMZ therapy as part of their standard treatment.\n* Males and Females â‰¥18 years of age at the time of signing the informed consent document. Able to understand consent forms and study materials in English\n* Willing to use approved methods of contraception for duration of study\n* Karnofsy Performance Score (KPS) of at least 60\n* Patients should have stopped any anti-depressant medications by standard of care at least a month before enrolling in the trial\n* Willing and able to adhere to the study visit schedule and other protocol requirements.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with other chemotherapy drugs for glioma\n* Known hypersensitivity to Mirtazapine and 5-HT3 receptor antagonists\n* Life expectancy of less than three months\n* Pregnancy or breastfeeding.",
    "miscellaneous_criteria": ""
}